Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,058 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06011109 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | recruiting | Phase 1 / Phase 2 | 30 | Aveta Biomics, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06132737 | [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients | recruiting | Phase 1 / Phase 2 | 15 | Pentixapharm AGINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07137494 | A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04547777 | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | recruiting | Phase 1 | 90 | Darell BignerOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05625594 | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT01269853 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | recruiting | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06254326 | ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients(ADAGiO) | recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06807619 | A Study of Sotorasib in People With Brain Tumors | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03750513 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06048094 | 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery(FACILITATE) | recruiting | Phase 1 | 46 | Baptist Health South FloridaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07599371 | A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | recruiting | Phase 1 | 20 | Juan P. Alderuccio, MDOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07003139 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors | recruiting | Phase 1 / Phase 2 | 10 | China Medical University HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06431685 | Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer | recruiting | Phase 1 | 10 | Sichuan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03988283 | Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors | recruiting | Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569042 | A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 15 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04540107 | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | recruiting | Phase 1 | 300 | Susan ChangOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06012695 | NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 79 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM(GBM 001) | recruiting | Phase 1 | 11 | Shayan Moosa, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03383978 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma(CAR2BRAIN) | recruiting | Phase 1 | 42 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04689048 | Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery | recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05366179 | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | recruiting | Phase 1 | 36 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05917145 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | recruiting | Phase 1 | 94 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT06126744 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252(PuMP) | recruiting | Phase 1 | 51 | Duke UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2026source: clinicaltrials